Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ayahuasca vs Esketamine in Major Depressive Disorder
NCT07212946Phase 2Completed
- Sponsor
- Universidade de São Paulo
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ayahuasca in major depressive disorder (MDD) (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Beck Depression Inventory at 49 days. Started Oct 2022; status: completed.
02
Drugs
ayahuasca
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07212946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212946.